Report of Foreign Issuer (6-k)
30 Junio 2020 - 6:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of June, 2020
Commission File Number: 001-36000
XTL Biopharmaceuticals
Ltd.
(Translation of registrant’s name
into English)
5 Badner St.
Ramat Gan,
4365603, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
RAMAT
GAN, Israel - (June 30, 2020) XTL Biopharmaceuticals Ltd. (the “Company”)
announces today the postponement of the extraordinary shareholders' meeting scheduled for June 30, 2020, since legal quorum requirements
as set forth in the meeting’s convening notice were not met.
The
Company has announced that the deferred extraordinary shareholders meeting will reconvene on July 7, 2020, at 10:00AM (Israel Standard
Time).
About XTL Biopharmaceuticals Ltd.
(XTL)
XTL Biopharmaceuticals
Ltd., is a clinical-stage biotech company. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset
for the treatment of autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren’s Syndrome (SS). The
few treatments currently on the market for these diseases are not effective enough for most patients and some have significant
side effects. hCDR1 has robust clinical data in three clinical trials with 400 patients and over 200 preclinical studies with data
published in more than 40 peer reviewed scientific journals.
XTL is traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 3 611 6666
Email: ir@xtlbio.com
www.xtlbio.com
===============================================================
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: June 30, 2020
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
By:
|
/s/ Shlomo Shalev
|
|
|
|
Shlomo Shalev
Chief Executive Officer
|
2
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
